Loading organizations...
Loading organizations...
Cerebral Therapeutics is a technology company.
Cerebral Therapeutics develops a novel drug-device combination therapy designed to treat adult refractory epilepsy. This innovative approach involves the intracerebroventricular delivery of a therapeutic agent, aiming to provide enhanced efficacy and reduced systemic toxicity compared to conventional treatments. The company focuses on a precise, targeted delivery method for managing uncontrolled neurological diseases.
The company was co-founded in 2013 by Dr. Thomas C. Sutula, M.D., Ph.D., and Dr. Gerald A. Grant, M.D., both recognized physician-scientists in the epilepsy field. Their foundational insight stemmed from the need for more effective and localized treatment options for patients whose seizures are not adequately controlled by existing oral medications. Their expertise informed the development of this specialized delivery platform.
Cerebral Therapeutics targets patients suffering from medically refractory epilepsy who have exhausted other treatment options. The company's long-term vision is to significantly improve the lives of individuals living with severe neurological disorders by providing more effective, less burdensome therapeutic solutions that offer better seizure control and quality of life.
Cerebral Therapeutics has raised $85.8M across 4 funding rounds.
Cerebral Therapeutics has raised $85.8M in total across 4 funding rounds.
Cerebral Therapeutics has raised $85.8M in total across 4 funding rounds.
Cerebral Therapeutics's investors include Weston Nichols, Granite Point Capital, Perceptive Advisors, RA Capital Management, Vivo Capital, Matthew Hammond, March Capital, Warren Lammert.
Cerebral Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for refractory neurological diseases, primarily through direct brain delivery of drugs via its proprietary ICVRx™ technology.[1][2][3] The company focuses on intracerebroventricular (ICV) administration of specialized formulations like its lead candidate CT-010, an anti-seizure medication for medically refractory epilepsy, bypassing blood-brain barrier limitations to maximize efficacy and minimize systemic exposure.[1][3][4] It serves patients with uncontrolled neurological disorders in the healthcare sector, addressing unmet needs where oral therapies fail due to poor brain penetration or toxicity.[1][2] Growth momentum includes a $40 million Series C financing in 2025 to fund Phase 2 trials and Phase 3 readiness, following a $35 million Series B, with ongoing international studies in Australia and Israel.[3][7]
Cerebral Therapeutics was founded in February 2018 by experts in neurology, neurosurgery, and drug delivery, based in Aurora, Colorado (with some sources noting roots as early as 2010).[1][2][4] The idea emerged from pioneers in neuroscience seeking to overcome traditional drug delivery challenges for central nervous system (CNS) disorders, leading to the development of ICV therapies delivered via an implanted infusion system.[2][3][4] Early traction came through venture backing as a life sciences startup, patent filings (21 total, focusing on ventricular delivery and dosage forms), and process automation to scale operations without heavy hiring.[1][2] Pivotal moments include launching a Phase 2b study for CT-010 in refractory epilepsy patients and securing Series B ($35M) and Series C ($40M) financings to advance clinical trials internationally.[3][4][7]
Cerebral Therapeutics rides the wave of advanced CNS drug delivery innovations, addressing the blood-brain barrier challenge amid a booming epilepsy pipeline (90+ therapies from 75+ companies, including CT-010 competitors like Kv7 and OV329).[1][5] Timing aligns with rising demand for refractory epilepsy treatments—affecting millions globally—fueled by market forces like aging populations, unmet needs in 30% drug-resistant cases, and investor interest in neurotech (evidenced by $75M+ in recent financings).[3][5][7] The company influences the ecosystem by pioneering ICV methods, potentially unlocking therapies for Alzheimer's, Parkinson's, and beyond, while collaborating with sites in Australia, Israel, and CU Anschutz, fostering a shift from systemic to targeted CNS interventions.[4]
Cerebral Therapeutics is poised to advance CT-010 into Phase 3 trials post-Series C funding, with U.S. expansion and pipeline growth targeting broader refractory neurological indications.[3][4] Trends like AI-driven biomarkers, combo drug-device models, and epilepsy market expansion (driven by novel MOAs) will shape its path, amid competition from NeuroPace and UCB.[5] Its influence may evolve by validating direct-brain delivery, catalyzing a new era for CNS therapeutics and improving outcomes for patients failed by conventional options—reinforcing its mission to transform refractory epilepsy care from the ground up.[1][3]
Cerebral Therapeutics has raised $85.8M across 4 funding rounds. Most recently, it raised $40.0M Series C in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 28, 2022 | $40.0M Series C | Weston Nichols | Granite Point Capital, Perceptive Advisors, RA Capital Management, Vivo Capital |
| Jan 1, 2020 | $35.0M Series B | Matthew Hammond | March Capital, Granite Point Capital, Weston Nichols, Vivo Capital |
| Mar 8, 2019 | $7.8M Series A Extension | Granite Point Capital, Vivo Capital | |
| Jun 1, 2018 | $3.0M Series A | Vivo Capital, Warren Lammert | March Capital |